Attorneys for the state of West Virginia and two remaining pharmaceutical manufacturers have reached a tentative $161.5 million settlement just as closing arguments were set to begin in a seven-week trial over the opioid epidemic, Attorney General Patrick Morrisey said Wednesday.
Morrisey announced the development in court in the state's lawsuit against Teva Pharmaceuticals Inc., AbbVie's Allergan and their family of companies. The judge agreed to put the trial on hold to give the parties the opportunity to work out a full settlement agreement in the upcoming weeks.
"Today does represent a very big day for our state," Morrisey said later at a news conference.
The trial started April 4. The lawsuit accused the defendants of downplaying the risks of addiction associated with opioid use while overstating the benefits.
Under the tentative deal, West Virginia would receive more than $134.5 million in cash, while Teva would supply the state with $27 million worth of Narcan, a medication that can reverse opioid overdoses, restore breathing and bring someone back to consciousness.
By reaching a settlement, "it obviously puts us in a position where we mitigate risk," Morrisey said. "We could win if we kept going to trial. I think we would have won. No guarantees, of course. But then we might be subject to five years of appeals and then we wouldn't see any resources for five years."
"I want to make sure we start to put feet on the ground now. And I want to see resources targeted to this epidemic now."
Under a plan announced by Morrisey in February, 72.5% of the settlement will go to a nonprofit foundation established to distribute money in opioid-related litigations, 24.5% would be allocated to local governments and 3% would go to the state. The foundation would consist of an 11-member board, including five state appointees and representatives from six regions of the state. The board members will have expertise in fields such as mental health, substance misuse and law enforcement.
West Virginia had reached a $99 million settlement with drugmaker Johnson & Johnson's subsidiary Janssen Pharmaceuticals Inc. last month over the drugmaker's role in perpetuating the opioid crisis in the state that has long led the nation in drug overdose deaths.